Merad Pharmaceuticals Limited - Accounts to registrar (filleted) - small 23.2.5

REGISTERED NUMBER: 04024112 (England and Wales)

Unaudited Financial Statements

for the Period 1 July 2022 to 30 September 2023

for

Merad Pharmaceuticals Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTOR:

Mrs N Kumar

REGISTERED OFFICE:

Lewis House

Great Chesterford Court

Great Chesterford

Essex

CB10 1PF

BUSINESS ADDRESS:

Reston House

Huntingdon Road

Cambridge

Cambridgeshire

CB3 0LH

REGISTERED NUMBER:

04024112 (England and Wales)

FIXED ASSETS

Tangible assets

5

-

47,104

CURRENT ASSETS

Debtors

6

218

10,425

Cash at bank

66,006

133,740

66,224

144,165

CREDITORS

Amounts falling due within one year

7

65,585

111,398

NET CURRENT ASSETS

639

32,767

TOTAL ASSETS LESS CURRENT LIABILITIES

639

79,871

PROVISIONS FOR LIABILITIES

-

88

NET ASSETS

639

79,783

CAPITAL AND RESERVES

Called up share capital

100

100

Retained earnings

539

79,683

SHAREHOLDERS' FUNDS

639

79,783

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 September 2023.

The members have not required the company to obtain an audit of its financial statements for the period ended 30 September 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 16 February 2024 and were signed by:

Mrs N Kumar - Director

1.	STATUTORY INFORMATION

Merad Pharmaceuticals Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2.	STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3.	ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements have been prepared under the historical cost convention.

The financial statement have not been prepared on going concern basis as a result of the company ceasing to trade.

As the financial statement have not been prepared on going concern basis:

Any cost associated with winding up the business have been recognised.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is charged at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Improvements to property - 2% on cost

Plant and machinery - 25% on reducing balance

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instruments.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes, in effect, a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Change of year end

The financial statements have been prepared for the longer period of 15 months and therefore the amounts presented in the financial statements (including the related notes) are not entirely comparable with the previous period of 12 months.

The reason for the longer period of reporting is that the company ceased trading on 30 September, 2023.

4.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 (2022 - 3 ) .

5.	TANGIBLE FIXED ASSETS

Improvements

to

Plant and

property

machinery

Totals

£

£

£

COST

At 1 July 2022

72,134

24,267

96,401

Disposals

(72,134

)

(24,267

)

(96,401

)

At 30 September 2023

-

-

-

DEPRECIATION

At 1 July 2022

25,496

23,801

49,297

Eliminated on disposal

(25,496

)

(23,801

)

(49,297

)

At 30 September 2023

-

-

-

NET BOOK VALUE

At 30 September 2023

-

-

-

At 30 June 2022

46,638

466

47,104

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2023

2022

£

£

Trade debtors

-

10,384

Other debtors

218

41

218

10,425

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2023

2022

£

£

Taxation and social security

7,859

21,900

Other creditors

57,726

89,498

65,585

111,398

Other creditors includes balances of £nil (2022 - £1,481) in respect of accruals and £nil (2022- £79,301) of balances due to a related company, £57,726 (2022 - £8,716) in respect of directors loan accounts.